Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2925MR)

This product GTTS-WQ2925MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ2925MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8305MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ15997MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ5092MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ2028MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AHLX-20
GTTS-WQ9040MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ7301MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FPA-008
GTTS-WQ3876MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ3444MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AZD8895
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW